Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
Journal of Health Economics and Outcomes Research
doi 10.36469/9808
Full Text
Open PDFAbstract
Available in full text
Date
November 29, 2017
Authors
Publisher
Columbia Data Analytics